Joish VN, et al. - In patients initiating somatostatin analogs (SSA) for carcinoid syndrome (CS), researchers determined the burden of carcinoid heart disease (CaHD) in this retrospective study. They investigated claims for commercially insured adults receiving SSA for CS between 2010 and 2016. Eligibility criteria included patients who had ≥ 1 medical claim for CS, had started SSA treatment, were continuously enrolled in their health plan for 30 days prior to SSA initiation and for ≥ 1 year, had no sign of acromegaly, and did not partake in a clinical trial during the study period. Among patients with CS, CaHD is common both before and after initiating SSA treatment. In order to reduce the CaHD burden, early diagnosis and control of CS are necessary.